SI21171A - Uporaba sevov parapoksvirusa ovis proti fibrozi organov - Google Patents

Uporaba sevov parapoksvirusa ovis proti fibrozi organov Download PDF

Info

Publication number
SI21171A
SI21171A SI200120047A SI200120047A SI21171A SI 21171 A SI21171 A SI 21171A SI 200120047 A SI200120047 A SI 200120047A SI 200120047 A SI200120047 A SI 200120047A SI 21171 A SI21171 A SI 21171A
Authority
SI
Slovenia
Prior art keywords
fibrosis
preventive
medicaments
preparation
human
Prior art date
Application number
SI200120047A
Other languages
English (en)
Slovenian (sl)
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of SI21171A publication Critical patent/SI21171A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200120047A 2000-07-11 2001-07-11 Uporaba sevov parapoksvirusa ovis proti fibrozi organov SI21171A (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
PCT/EP2001/007978 WO2002004019A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen

Publications (1)

Publication Number Publication Date
SI21171A true SI21171A (sl) 2003-10-31

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200120047A SI21171A (sl) 2000-07-11 2001-07-11 Uporaba sevov parapoksvirusa ovis proti fibrozi organov

Country Status (30)

Country Link
US (1) US6632647B2 (cs)
EP (1) EP1303302B1 (cs)
JP (1) JP5106736B2 (cs)
CN (1) CN1452496B (cs)
AR (1) AR028800A1 (cs)
AU (2) AU2001285827B2 (cs)
BG (1) BG107447A (cs)
CA (1) CA2415399C (cs)
CZ (1) CZ200372A3 (cs)
DK (1) DK200300014A (cs)
EE (1) EE200300019A (cs)
FI (1) FI20030038A7 (cs)
GB (1) GB2383752B (cs)
HK (1) HK1054330B (cs)
HR (1) HRP20030097A2 (cs)
HU (1) HU227668B1 (cs)
IL (1) IL153826A0 (cs)
LT (1) LT5064B (cs)
LU (1) LU90996B1 (cs)
LV (1) LV12991B (cs)
MA (1) MA25765A1 (cs)
MX (1) MXPA03000278A (cs)
NO (1) NO20030081L (cs)
NZ (1) NZ523535A (cs)
PL (1) PL360839A1 (cs)
RU (1) RU2003104522A (cs)
SE (1) SE0300033L (cs)
SI (1) SI21171A (cs)
SK (1) SK382003A3 (cs)
WO (1) WO2002004019A2 (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1499355A4 (en) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2012045473A1 (en) * 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
WO2017141942A1 (ja) * 2016-02-16 2017-08-24 国立大学法人大阪大学 線維化を治療するための医薬組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis;PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2125846T3 (es) * 1996-04-15 2001-12-16 Anton Prof Dr Med Vet Dr Mayr Nuevas indicaciones para el empleo de inductores de parainmunidad multipotentes a partir de virus de viruela o virus de paraviruela atenuados, no inmunogenos, como medicamento.
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
EP1303302A2 (de) 2003-04-23
EP1303302B1 (de) 2009-10-14
HUP0303830A2 (hu) 2004-04-28
FI20030038A7 (fi) 2003-03-10
HU227668B1 (en) 2011-11-28
HUP0303830A3 (en) 2004-10-28
US20020076418A1 (en) 2002-06-20
WO2002004019A2 (de) 2002-01-17
US6632647B2 (en) 2003-10-14
PL360839A1 (pl) 2004-09-20
CZ200372A3 (cs) 2003-05-14
SE0300033L (sv) 2003-03-10
LU90996B1 (en) 2003-01-08
LV12991B (en) 2003-08-20
GB0302629D0 (en) 2003-03-12
DK200300014A (da) 2003-03-07
CN1452496B (zh) 2012-10-10
LT2003008A (en) 2003-07-25
JP2004502741A (ja) 2004-01-29
HK1054330A1 (en) 2003-11-28
SK382003A3 (en) 2003-07-01
HK1054330B (zh) 2005-07-15
GB2383752A (en) 2003-07-09
EE200300019A (et) 2004-10-15
MA25765A1 (fr) 2003-04-01
MXPA03000278A (es) 2004-04-05
NO20030081D0 (no) 2003-01-08
CN1452496A (zh) 2003-10-29
JP5106736B2 (ja) 2012-12-26
WO2002004019A3 (de) 2002-08-01
LT5064B (lt) 2003-11-25
RU2003104522A (ru) 2004-06-27
BG107447A (bg) 2003-09-30
SE0300033D0 (sv) 2003-01-10
IL153826A0 (en) 2003-07-31
GB2383752B (en) 2004-11-24
HRP20030097A2 (en) 2005-02-28
AR028800A1 (es) 2003-05-21
NZ523535A (en) 2004-12-24
AU2001285827B2 (en) 2006-11-30
AU8582701A (en) 2002-01-21
CA2415399C (en) 2011-11-08
NO20030081L (no) 2003-01-08
CA2415399A1 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
CN102858959B (zh) 溶瘤弹状病毒
JP7399976B2 (ja) Covid-19新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用
JP5106736B2 (ja) 臓器線維形成に対するパラポックスウイルスovis株の使用
JP5950964B2 (ja) 臓器線維形成に対するパラポックスウイルスovis株の使用
EP4248986A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
CN111329859B (zh) 叶绿素铜钠盐在制备用于抗肠道病毒的药物中的应用
CN117122693A (zh) 经酸酐修饰的蛋白质抑制痘病毒的方法
CN112843073A (zh) 瑞德西韦(Remdesivir)在制备抗牛副流感病毒3型药物中的应用
WO2009097138A1 (en) Antiviral compositions and methods of treatment
US20060204600A1 (en) Dragon's blood anti-viral materials and methods
CN116098916B (zh) 马立巴韦在制备抗h13亚型aiv药物中的应用
HK1060050A (en) Use of strains of the parapox ovis virus against organ fibrosis
CN112353809B (zh) 一种黄芪甲苷类化合物的药物用途
CN118526483A (zh) 一种天然植物来源的联苯多酚化合物在制备治疗疱疹性疾病的药物中的应用
WO2022000167A1 (zh) 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
CN118105384A (zh) 表告依春在抗mrv中的应用
WO2021224836A1 (en) A synergistic formulation for management of respiratory pathogens including coronaviruses
Yang et al. Type I interferons triggered through the TLR3-TRIF pathway control
İnan SOME DRUGS USED IN THE COVID-19 OUTBREAK AND TREATMENT
Kojima An Extract from Spirulina platensis is a Selective Inhibitor of Herpes Simplex Virus Type
WO2016133560A1 (en) Recombinant human cc10 protein for treatment of influenza and ebola

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20070226